Nifediac CC┬« Extended-release Tablets, USP are an extended release tablet dosage form of the calcium channel blocker nifedipine. The product is provided as a general matrix tablet with a polymer coating. Nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-,dimethyl ester.
Nifediac CC┬« Extended-release Tablets, USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Published Studies Related to Nifediac (Nifedipine)
Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II
essential hypertension: a randomized placebo-controlled trial. 
the treatment of patients with essential hypertension... CONCLUSIONS: Vitamin D supplementation can reduce blood pressure in patients with
Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy:
a randomized controlled trial. 
hypertensive emergency of pregnancy... CONCLUSION: As administered in this trial, oral nifedipine lowered blood pressure
Effect of nifedipine on choroidal blood flow regulation during isometric
healthy subjects... CONCLUSIONS: In conclusion, the data of the present study suggest that nifedipine
Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. [2011.11]
Intravenous hydralazine is a commonly administered arteriolar vasodilator that is effective for hypertensive emergencies associated with pregnancy...
Adjuvant Tamsulosin or Nifedipine After Extracorporeal Shock Wave Lithotripsy for Renal Stones: A Double Blind, Randomized, Placebo-controlled Trial. [2011.11]
OBJECTIVE: To evaluate the effects of the adjuvant use of tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for nonlower pole kidney stones 5-20 mm in size... CONCLUSION: The stone-free rates after extracorporeal shock wave lithotripsy with adjuvant tamsulosin or nifedipine were significantly increased only for nonlower pole renal stones 10-20 mm in size compared with placebo. Nifedipine was associated with more adverse effects than placebo. Copyright A(c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Nifediac (Nifedipine)
Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour [Recruiting]
Preterm birth is the leading cause of perinatal mortality and morbidity. According to WHO,
15 million children are born prematurely (gestational age < 37 weeks) in the world each year
while 7% of them die because of complications associated with prematurity. Despite constant
improvement of obstetrical care, the number of preterm births has increased over the last
decades and prematurity is still the most frequent cause of prenatal hospitalization in
The American College of Obstetricians and Gynecologists as well as the Royal College of
Obstetricians and Gynaecologists recommend nifedipine as a first-line tocolytic in case of
acute threatened preterm labour. Clinical experience show however an important variability
in treatment response among pregnant women. In spite of its large use in obstetrics as a
tocolytic agent, nifedipine is prescribed off-label. As a consequence no international
consensus on optimal dose schedule has so far been proposed.
Small sample size and heterogeneousness of tocolysis administration protocols make it
difficult to compare the little data available on the pharmacokinetics of nifedipine in
pregnant women. Nevertheless an important interindividual variability in concentrations has
been identified (CV=12-76%) but very few studies have investigated the possible reasons of
this variability in pregnant women. Genetic and environmental factors involved in drug
distribution and metabolism (e. g. enzymatic activity, CYP 3A5 genotype) might partially
explain variability in drug levels and therefore differences in treatment response.
The goal of this study is to quantify the variability in nifedipine pharmacokinetics and
identify potential genetic and non-genetic sources of variability in nifedipine
pharmacokinetics in pregnant women. The relationship between concentration and treatment
response will be evaluated and will serve to propose optimal dosage regimen to improve
efficacy and reduce side effects associated with this treatment.
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed [Completed]
Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence
of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the
corresponding loose combination under fed conditions.
Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions [Completed]
The present study will be performed to investigate and to compare the in-vivo performance of
the two investigational products Gen-nifedipine extended release, (previously referred to as
Gen-Nifedipine XL (Genpharm ULC, Canada)) and Nifedipine(Bayer Healthcare AG manufactured
as Adalat« XL«, Adalat« LA, Adalat« Crono, Adalat« OROS) by comparing their pharmacokinetic
parameters after oral single dose administrations in the fasted and fed state.
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil [Not yet recruiting]
This study examines the efficacy and safety of the Fixed Dose combination BAY98-7106
(nifedipine plus candesartan) in patients with hypertension, who do not achieve adequate
control of blood pressure with candesartane alone.
Patients meeting the entry criteria, will receive candesartan alone 16mg in the first five
weeks of the study to assess blood pressure control with candesartan given alone.
Patients with an insufficient therapeutic response to candesartan alone (defined by mean
seated systolic blood pressure >/=140 mm/Hg) will enter the next part of the study, and will
be randomly assigned to one of 3 treatments ( candesartan alone 16mg, combination nifedipine
/ candesartan 30/16 mg, combination nifedipine / candesartan 60/16 mg). Neither patient nor
the treating physician will know which treatment is given (double-blinded design).This part
of the study will last eight weeks
Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor [Recruiting]
This study looks at the effects of a mother's genes and other characteristics (mother's age,
baby's age, race, and other diseases) on the ability of nifedipine to end contractions and
prevent an early delivery. This information will be used to decide what amount of
nifedipine women need to best treat preterm contractions.